Patent · US Active

5-HT2B antagonists

US9751845B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

National Institute of Biological Sciences, Beijing · CN

Inventors

Niu Huang · Beijing, CN
Yu Zhou · Beijing, CN
Xingyu Lin · Beijing, CN

Key dates

Filing date	Oct 13, 2016
Grant date	Sep 5, 2017
Priority date	—
Expiry date	Oct 13, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D251/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I:and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.